K-V Pharmaceutical (KV-a) Surges on FDA Guidance on Makena

July 2, 2012 9:30 AM EDT Send to a Friend
Get Alerts KV-A Hot Sheet
Trade KV-A Now!
Join SI Premium – FREE
K-V Pharmaceutical (NYSE: KV-A) (NYSE: KV-B) is booming in pre-open trading Monday after the FDA provided further guidance about Makena.

According to the company, FDA provides further guidance to healthcare providers and pregnant women at high risk for recurrent preterm birth, recommending the use of FDA-approved Makena® rather than compounded drug formulations of hydroxyprogesterone caproate. The agency also describes its enforcement policy towards compounded formulations of hydroxyprogesterone caproate.

Shares of KV last traded at $0.84, up 48 percent.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

FDA, Momentum Movers

Add Your Comment